Complicated Intra-abdominal Infection
📧 Sign up to get email alerts when something new happens for Complicated Intra-abdominal Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-24Clinical Trial Update: EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection. [Phase 3]
A Phase 3 trial comparing extended antibiotic durations to standard durations for complicated intra-abdominal infection is ongoing but not c…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales [Phase 3]
A Phase 3 clinical trial update reporting completion of studies evaluating Cefepime/Nacubactam and Aztreonam/Nacubactam vs best available th…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants [Phase 2]
A Phase 2 study assessing safety, tolerability, and pharmacokinetics of cefiderocol in hospitalized pediatric participants has completed wit…
-
EMA approval · 2026-01-26EMA Authorised: Recarbrio (imipenem monohydrate;cilastatin sodium;relebactam monohydrate) — Merck Sharp & Dohme B.V.
EMA authorised Recarbrio (imipenem/cilastatin/relebactam) for use in Gram-negative bacterial infections, including hospital-acquired/ventila…
-
EMA approval · 2025-10-22EMA Authorised: Tygacil (tigecycline) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Tygacil (tigecycline) for use in bacterial infections, including complicated skin and soft tissue i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
Pfizer is conducting a post-market study in Korea to gather information about Zavicefta (ceftazidime-avibactam) after it was released, cover…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections [Phase 3]
Phase 3 trial is recruiting to assess efficacy and safety of meropenem plus pralubactam for carbapenem-resistant Enterobacteriaceae infectio…
-
FDA approval · 2025-02-28FDA Approved: AVYCAZ — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for AVYCAZ (ceftazidime-avibactam) from Allergan, Inc., authorizing changes to the approved labeling…
-
CLINICAL_TRIALS research · 2024-12-24Clinical Trial Update: EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection. [Phase 3]
A Phase 3 clinical trial is evaluating whether extending antibiotic duration beyond standard durations improves outcomes for patients with c…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. [Phase 3]
Phase 3 study evaluating aztreonam-avibactam ± metronidazole versus meropenem ± colistin for serious Gram-negative infections, including com…
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection [Phase 3]
Phase 3 trial evaluating PF-06947386 for efficacy and safety in Japanese adults with complicated intra-abdominal infection has completed wit…
-
FDA approval · 2024-01-26FDA Approved: AVYCAZ — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for AVYCAZ (ceftazidime-avibactam) filed by Allergan, Inc.
-
FDA approval · 2023-01-27FDA Approved: ERTAPENEM — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for ertapenem submitted by Eugia US LLC, authorizing changes to its approved labeling and/or ind…
-
FDA approval · 2022-08-18FDA Approved: MEROPENEM — Original Application (BROOKS STERISCIENCE LIMITED)
FDA approves Brooks SterisScience Limited's original application for generic meropenem (Meropenem) for multiple susceptible bacterial infect…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) [Phase 2]
Phase 2 trial update comparing MK-7625A plus metronidazole vs meropenem in pediatric patients with complicated intra-abdominal infection has…
-
FDA approval · 2021-07-29FDA Approved: ZOSYN IN GALAXY CONTAINERS — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application to allow Zosyn (piperacillin/tazobactam) to be supplied in Galaxy containers, by Wyeth Pharmaceutica…
-
FDA approval · 2020-05-25FDA Approved: VABOMERE — Supplemental Application (Melinta Therapeutics, LLC)
The FDA approved a supplemental application for VABOMERE (meropenem-vaborbactam) from Melinta Therapeutics to modify/expand its labeling.
-
CLINICAL_TRIALS trial_result · 2019-10-08Clinical Trial Update: LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI) [Phase 2]
Phase 2 trial update for LYS228 in complicated intra-abdominal infection (cIAI) evaluating pharmacokinetics, clinical response, safety and t…
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) [Phase 3]
Phase 3 trial evaluating efficacy and safety of imipenem/cilastatin/relebactam (MK-7655A) in Japanese participants with complicated intra-ab…
-
FDA approval · 2019-07-16FDA Approved: RECARBRIO — Original Application (Merck Sharp & Dohme LLC)
FDA approved RECARBRIO (imipenem/cilastatin/relebactam) under NDA 212819 from Merck Sharp & Dohme LLC, marking the original approval of this…
-
FDA approval · 2019-06-03FDA Approved: ZERBAXA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for ZERBAXA (ceftolozane and tazobactam) from Merck, resulting in changes to the product labeling.
-
FDA approval · 2019-03-14FDA Approved: AVYCAZ — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for AVYCAZ (ceftazidime-avibactam) that updates labeling in connection with the supplement.
-
FDA approval · 2018-08-27FDA Approved: XERAVA — Original Application (Tetraphase Pharmaceuticals, Inc.)
The FDA approved Xerava (eravacycline) from Tetraphase Pharmaceuticals in an original application for the treatment of complicated intra-abd…
-
CLINICAL_TRIALS trial_result · 2018-07-12Clinical Trial Update: Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013) [Phase 3]
Phase 3 trial of ceftolozane/tazobactam plus metronidazole in Japanese adults with complicated intra-abdominal infection has completed with …
-
CLINICAL_TRIALS trial_result · 2018-07-03Clinical Trial Update: Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections [Phase 2]
A Phase 2 multicenter, double-blind trial comparing NXL104/Ceftazidime + Metronidazole versus Meropenem for complicated intra-abdominal infe…